Efficiency of Ginnalin A in an inflammatory-induced colitis model

Ginnalin A 在炎症诱导的结肠炎模型中的功效

• 批准号: 520535-2017
• 负责人: Fortier, Isabelle
• 金额: $ 1.82万
• 依托单位: C.E.G.E.P. Lévis-Lauzon
• 依托单位国家: 加拿大
• 项目类别: Applied Research and Development Grants - Level 1
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=641215
• 关键词: Efficiency; Ginnalin; inflammatory; induced; colitis

This project aims to assess the biological efficacy of Ginnalin A, a phenolic antioxidant compound extracted from red maples buds, in the treatment of inflammatory bowel disease using a murine model. TransBIOTech will first perform a standard pharmacokinetic analysis of Ginnalin A to establish compound bioavailability and proper dosage for the efficacy study. Using the DSS-induced colitis murine model, TransBIOTech will further establish the capability of Ginnalin A at reducing the model associated symptoms at the macroscopical, histological and biochemical levels.

该项目旨在利用小鼠模型评估 Ginnalin A（一种从红枫花蕾中提取的酚类抗氧化化合物）在治疗炎症性肠病方面的生物功效。 TransBIOTech 将首先对 Ginnalin A 进行标准药代动力学分析，以确定化合物的生物利用度和药效研究的适当剂量。使用 DSS 诱导的结肠炎小鼠模型，TransBIOTech 将进一步确定 Ginnalin A 在宏观、组织学和生化水平上减轻模型相关症状的能力。